News

Under the terms of the acquisition agreement, which was announced on December 23, 2008, Volcano paid approximately $21.5 million in cash at closing. Axsun will operate as a

Mr Camaratta has held various senior marketing and operations executive positions over the past 25 years at Siemens Medical Solutions in both the US and Germany. Mr Camaratta

While the workforce reductions will take place across the organization, the company will maintain core competencies in the research, development and product operations areas in order to support

The FDA 510(k) clearance has been granted based on its premarket notification for indications for the use of elevating tissue temperature and temporary relief of muscle and joint

Lilly is continuing to work with the agency on the new drug application (NDA). The FDA does not require any additional clinical trials for the continued review of

Proceeds from the financing will be used to accelerate development of Atrimers, a new class of protein therapeutics that the company is developing to address significant unmet medical

His resignation, effective January 9, 2009, follows an 11-year career with Acusphere, in which he oversaw the company’s clinical trials for its lead product candidate, Imagify for injectable

Numoda is currently managing Columbia’s ongoing Pregnant study of Prochieve 8% (progesterone gel) to reduce the risk of preterm birth in women with a short cervix at mid-pregnancy.

KMD-3213 is a selective alpha 1A-adrenoceptor antagonist originally discovered by Kissei Pharmaceutical Co. It was developed by Daiichi Sankyo and Kissei Pharmaceutical and is jointly marketed as Urief